BTG (LON:BTG) announced its earnings results on Tuesday. The company reported GBX 32.90 ($0.45) EPS for the quarter, topping the consensus estimate of GBX 29.80 ($0.40) by GBX 3.10 ($0.04), Bloomberg Earnings reports. BTG had a net margin of 15.50% and a return on equity of 10.80%.
BTG opened at GBX 636.50 ($8.63) on Thursday, according to MarketBeat Ratings. BTG has a 12-month low of GBX 559.82 ($7.59) and a 12-month high of GBX 784 ($10.63).
Several brokerages have commented on BTG. Deutsche Bank downgraded shares of BTG to a “hold” rating and dropped their target price for the stock from GBX 810 ($10.99) to GBX 645 ($8.75) in a report on Thursday. JPMorgan Chase dropped their target price on shares of BTG from GBX 680 ($9.22) to GBX 650 ($8.82) and set a “neutral” rating on the stock in a report on Wednesday. Numis Securities restated a “buy” rating and set a GBX 840 ($11.39) target price on shares of BTG in a report on Tuesday. Jefferies Group raised their target price on shares of BTG from GBX 775 ($10.51) to GBX 900 ($12.21) and gave the stock a “buy” rating in a report on Tuesday. Finally, Shore Capital restated a “buy” rating on shares of BTG in a report on Tuesday. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. BTG presently has an average rating of “Buy” and a consensus target price of GBX 761.14 ($10.32).
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.